EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

David J Jackson iD, Michael E Wechsler, Daniel J Jackson, David Bernstein, Stephanie Korn, Paul E Pfeffer iD, Ruchong Chen, Junpei Saito, Gustavo de Luíz Martinez, Lucyna Dymek, Loretta Jacques, Nicholas Bird und 7 weitere

New England Journal of Medicine · 19.12.2024 · 391 (24) · 2337-2349

DOI: 10.1056/nejmoa2406673 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 19.12.2024. Verfasst von David J Jackson und 18 weiteren Autor:innen. Beteiligte Einrichtung: From Guy's Severe Asthma Centre, Guy's and St. Thomas' NHS Foundation Trust, and the School of Immunology and Microbial Sciences, King's College Lond…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized, Asthma, Eosinophilia. Die Arbeit wurde bisher 162-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaEosinophiliaAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodDrug Administration ScheduleEosinophilsForced Expiratory VolumeInjections, SubcutaneousInterleukin-5Leukocyte CountSeverity of Illness IndexDisease ProgressionAdolescentYoung Adult

Substanzen

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedInterleukin-5

Autor:innen und Institutionen

  • From Guy's Severe Asthma Centre, Guy's and St. Thomas' NHS Foundation Trust, and the School of Immunology and Microbial Sciences, King's College London (David J. Jackson), Barts Health NHS Trust (P.E.P.), and GSK (L.J.,…

ORCID-Profile: David J Jackson, Paul E Pfeffer

Förderung

  • GlaxoSmithKline

Zitieren

APA

Jackson, D. J., Wechsler, M. E., Jackson, D. J., Bernstein, D., Korn, S., Pfeffer, P. E., Chen, R., Saito, J., de Luíz Martinez, G., Dymek, L., Jacques, L., Bird, N., Schalkwijk, S., Smith, D., Howarth, P., Pavord, I. D., SWIFT-1 and SWIFT-2 Investigators, SWIFT-1 Investigators, & SWIFT-2 Investigators (2024). Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. New England Journal of Medicine, 391(24), 2337-2349. https://doi.org/10.1056/nejmoa2406673

Vancouver

Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. New England Journal of Medicine. 2024;391(24):2337-2349. doi:10.1056/nejmoa2406673

BibTeX
@article{Jackson2024,
  author = {Jackson, David J and Wechsler, Michael E and Jackson, Daniel J and Bernstein, David and Korn, Stephanie and Pfeffer, Paul E and Chen, Ruchong and Saito, Junpei and de Luíz Martinez, Gustavo and Dymek, Lucyna and Jacques, Loretta and Bird, Nicholas and Schalkwijk, Stein and Smith, Douglas and Howarth, Peter and Pavord, Ian D and SWIFT-1 and SWIFT-2 Investigators, SWIFT-1 and SWIFT-2 Investigators and SWIFT-1 Investigators, SWIFT-1 Investigators and SWIFT-2 Investigators, SWIFT-2 Investigators},
  title = {Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {24},
  pages = {2337--2349},
  doi = {10.1056/nejmoa2406673}
}
Kostenlos starten →